A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 4, 2010, Pages

  Taylor, Sandra L ^a   Ganti, Sheila ^a   Bukanov, Nikolay O ^d   Chapman, Arlene ^e   Fiehn, Oliver ^c   Osier, Michael ^f   Kim, Kyoungmi ^a   Weiss, Robert H ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENZYME CORPORATION   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; KIDNEY POLYCYSTIC DISEASE; METABOLOMICS; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PURINE METABOLISM; TIME OF FLIGHT MASS SPECTROMETRY; TRYPTOPHAN METABOLISM;

EID: 77950798255     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00722.2009     Document Type: Article

References (54)

1. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1: 64-69, 2006.
2. Belibi FA, Edelstein CL. Unified ultrasonographic diagnostic criteria for polycystic kidney disease. J Am Soc Nephrol 20: 6-8, 2009.
3. Bontemps F, Van den Berghe G, Hers HG. Evidence for a substrate cycle between AMP and adenosine in isolated hepatocytes. Proc Natl Acad Sci USA 80: 2829-2833, 1983.
4. Boulesteix AL. PLS dimension reduction for classification with micro-array data. Stat Appl Genet Mol Biol 3: 33, 2004.
5. Boulesteix AL. WilcoxCV: an R package for fast variable selection in cross-validation. Bioinformatics 23: 1702-1704, 2007.
6. Calvet JP. Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol 3: 1205-1211, 2008.
7. Cerecedo LR, Allen FW. Studies on purine metabolism. III. The fate of guanosine and adenosine in the dog. J Biol Chem 107: 421-424, 1934.
8. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 3: 1197-1204, 2008.
9. Chapman AB, Torres VE, Grantham JJ, Shoaf SE, Ouyang JJ, Czerweic FS. A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA), in patients with ADPKD (Abstract). J Am Soc Nephrol 16: 68A, 2005.
10. Dettmer K, Hammock BD. Metabolomics - a new exciting field within the "omics" sciences. Environ Health Perspect 112: A396-A397, 2004.
11. Fiehn O, Wohlgemuth G, Scholz M. Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. Proc Lect Notes Bioinformatics 3615: 224-239, 2005.
12. Fiehn O, Wohlgemuth G, Scholz M, Kind T, Lee dY, Lu Y, Moon S, Nikolau B. Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J 53: 691-704, 2008.
13. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, Guay-Woodford LM, Bae KT. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 73: 108-116, 2008.
14. Gruber J, Tang SY, Jenner AM, Mudway I, Blomberg A, Behndig A, Kasiman K, Lee CY, Seet RC, Zhang W, Chen C, Kelly F, Halliwell B. Allantoin in human plasma, serum and nasal lining fluids as a biomarker of oxidative stress; avoiding artifacts and establishing real in vivo concentrations. Antioxid Redox Signal 2009.
15. Heyne N, Benohr P, Muhlbauer B, Delabar U, Risler T, Osswald H. Regulation of renal adenosine excretion in humans - role of sodium and fluid homeostasis. Nephrol Dial Transplant 19: 2737-2741, 2004.
16. Ibraghimov-Beskrovnaya O, Bukanov N. Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci 65: 605-619, 2008.
17. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-D360, 2009.
18. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8: 558-570, 2009.
19. Kim KM, Henderson GN, Frye RF, Galloway CD, Brown NJ, Segal MS, Imaram W, Angerhofer A, Johnson RJ. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877: 65-70, 2009.
20. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol 4: 93-102, 2008.
21. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 363: 185-195, 2007.
22. Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 76: 89-96, 2009.
23. Lanz C, Patterson AD, Slavik J, Krausz KW, Ledermann M, Gonzalez FJ, Idle JR. Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. Radiat Res 172: 198-212, 2009.
24. Lawson CR, Doulton TW, MacGregor GA. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 7: 139-145, 2006.
25. Leal JF, Ferrer I, Blanco-Aparicio C, Hernandez-Losa J, Ramon YC, Carnero A, Lleonart ME. S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis 29: 2089-2095, 2008.
26. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 52: 117-123, 2008.
27. Maletic-Savatic M, Vingara LK, Manganas LN, Li Y, Zhang S, Sierra A, Hazel R, Smith D, Wagshul ME, Henn F, Krupp L, Enikolopov G, Benveniste H, Djuric PM, Pelczer I. Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol 73: 389-401, 2008.
28. Mangoo-Karim R, Uchic ME, Grant M, Shumate WA, Calvet JP, Park CH, Grantham JJ. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J 3: 2629-2632, 1989.
29. Mardia KV, Kent JT, Bibby JM. Multivariate Analysis. Amsterdam: Academic, 1979.
30. Mejias E, Navas J, Lluberes R, Martinez-Maldonado M. Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. Am J Med Sci 297: 145-148, 1989.
31. Moreno S, Ibraghimov-Beskrovnaya O, Bukanov NO. Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle 7: 1856-1864, 2008.
32. Nguyen DV, Rocke DM. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 18: 1625-1632, 2002.
33. Park JY, Schutzer WE, Lindsley JN, Bagby SP, Oyama TT, Anderson S, Weiss RH. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol 8: 12, 2007.
34. Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E. Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 29: 1213-1222, 2004.
35. Perroud B, Ishimaru T, Borowsky AD, Weiss RH. Grade-dependent proteomic characterization of kidney cancer. Mol Cell Proteomics 8: 971-985, 2009.
36. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64, 2006.
37. Petry KG, Reichardt JK. The fundamental importance of human galactose metabolism: lessons from genetics and biochemistry. Trends Genet 14: 98-102, 1998.
38. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824-827, 1994.
39. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 2143-2160, 2007.
40. Schmidt C. Metabolomics takes its place as latest up-and-coming "omic" science. J Natl Cancer Inst 96: 732-734, 2004.
41. Scholz M, Fiehn O. SetupX - a public study design database for metabolomic projects. Pacific Symp Biocomp 12: 169-180, 2007.
42. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, Weishaupt D, Tschirch F. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8: 13, 2007.
43. Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Kronig C, Schermer B, Benzing T, Cabello OA, Jenny A, Mlodzik M, Polok B, Driever W, Obara T, Walz G. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 37: 537-543, 2005.
44. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17: 2821-2831, 2006.
45. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914, 2009.
46. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochim Biophys Acta 1763: 1733-1748, 2006.
47. Taniai H, Sumi S, Ito T, Ueta A, Ohkubo Y, Togari H. A simple quantitative assay for urinary adenosine using column-switching high-performance liquid chromatography. Tohoku J Exp Med 208: 57-63, 2006.
48. Taylor M, Johnson AM, Tison M, Fain P, Schrier RW. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 46: 415-423, 2005.
49. Torres VE. New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 7: 159-169, 1998.
50. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261: 17-31, 2007.
51. Valkova N, Yunis R, Mak SK, Kang K, Kultz D. Nek8 mutation causes over-expression of galectin-1, sorcin, andvimentin and accumulation o fthe major urinary protein in renal cysts of jck mice. Mol Cell Proteomics 4: 1009-1018, 2005.
52. Wahl PR, Le HM, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP. Mitotic activation of Akt signalling pathway in Han: SPRD rats with polycystic kidney disease. Nephrology (Carlton) 12: 357-363, 2007.
53. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. York: Wiley, 1993.
54. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430, 2004.